SkinBioTherapeutics PLC AxisBiotix-Ps(TM) food supplement study commences (4501P)
February 17 2021 - 5:36AM
UK Regulatory
TIDMSBTX
RNS Number : 4501P
SkinBioTherapeutics PLC
17 February 2021
17 February 2021
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
AxisBiotix-Ps(TM) food supplement consumer study commences
-- Final study size of 265 from initial target of 200, following high demand for places
-- AxisBiotix-Ps(TM) shipped to participants, with study to commence upon receipt of supplements
SkinBioTherapeutics plc (AIM: SBTX ) , a life science company
focused on skin health, announces that AxisBiotix Limited, a wholly
owned subsidiary of the Company, has commenced its
AxisBiotix-Ps(TM) food supplement consumer study.
Further to research exploring the relationship between the gut
and the skin, SkinBioTherapeutics, with its partner Winclove
Probiotics B.V., developed a blend of bacterial strains in the form
of a food supplement. The proprietary blend of bacterial strains
has been specifically designed to balance the gut microbiome to
address the over-production of new skin cells often seen in
aggressive skin conditions such as psoriasis.
The food supplement blend has been named AxisBiotix-Ps(TM), and
enrolment for a 'self-managed' consumer study of the supplement
commenced in January 2021. Following an extremely high level of
demand for participation in the study, the capacity was increased
from 200 to 265 participants with the additional 65 places
focussing on non-psoriatic conditions to explore the possible
impact of probiotics on other skin conditions. The study will be
monitored through a bespoke mobile device app, allowing for the
study to progress amid COVID-19 restrictions.
Participants have been grouped into cohorts and supplements have
been shipped to the first cohort who, upon receipt, will download
the AxisBiotix -Ps(TM) 'BRIGHT' consumer study mobile device
application and commence the study. Participants will receive two
batches of supplements, each batch comprising 28 days of supply.
After each 7-day cycle, participants will be asked to respond to
questions on the app, evaluating the progression of their symptoms,
and will have the option to upload photos of the affected skin
areas.
Following the 2 x 28-day periods, there will be a period of
approximately 14 days where participants will continue to evaluate
the progress of their symptoms, in order to assess the effects
following cessation of taking the supplement.
The study is targeted to conclude by the end of April 2021 and,
following analysis of the data, the Company expects to be able to
report on the study findings shortly thereafter. Subject to a
positive outcome, the Company will then target a commercial launch
of the product during the course of 2021.
Stuart Ashman, CEO of SkinBioTherapeutics, said:
"I am extremely proud that, despite the global impact of
COVID-19 restrictions and the new import regulations pertaining to
Brexit, we have received the study samples of AxisBiotix-Ps (TM),
from our partners at Winclove, and have begun shipping the units to
the study participants. It is a reflection of the hard work of the
team that we have managed to deliver on our target of commencing
the food supplement consumer study by mid-Q1, despite these
external factors.
"The increased size of the study allows us to widen our scope to
assess the impact of AxisBiotix-Ps on the symptoms of other skin
conditions beyond psoriasis; this is an exciting scope of research
that will run concurrently with the primary trajectory of
AxisBiotix-Ps.
"We look forward to engaging directly with the study
participants and monitoring the impact of AxisBiotix-Ps on their
skin and overall health."
-Ends-
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161
Stuart J . Ashman, CEO 468 2760
Doug Quinn, CFO
Cenkos Securities Plc (Nominated Adviser Tel: +44 (0) 20 7397
& Broker) 8900
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)
Instinctif Partners Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Phillip Marriage 2020
/ Nathan Billis SkinBio@instinctif.com
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Prof. Catherine
O'Neill and Professor Andrew McBain.
The Company has demonstrated, through scientific testing, that
the SkinBiotix(R) platform can improve the barrier effect of skin
models, protect from infection and repair wounds. Proof of
principle studies have also shown that the SkinBiotix(R) platform
has beneficial attributes applicable to each of these areas. The
technology achieved positive results in clinical studies in human
volunteers in early 2019.
The Company listed on AIM in April 2017 and is based in
Manchester, UK. For more information, visit: www.skinbiotix.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESFDLFFFLLXBBF
(END) Dow Jones Newswires
February 17, 2021 06:36 ET (11:36 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024